title: [Clinical analysis of nosocomial infection of extended spectrum beta-lactamase-producing bacteria].
abstract: OBJECTIVE
  To investigate the clinical characteristics of nosocomial infection of extended spectrum beta-lactamase(ESBL)- producing bacteria.
  
  
  METHODS
  The data of 50 cases of ESBL(+) E. coli and K. pneumonia from January to November 1999 in Peking Union Medical Hospital were analysed; 45 cases of ESBL (-) infection were randomly selected as controls. t-test and chi-square tests were used for statistical analysis.
  
  
  RESULTS
  Long time hospitalization and use of the third generation cephalosporins were risk factors for ESBL(+) pathogen infection(P < 0.02); the prevalence of ESBL(+) bacteria infection in abdominal and pelvic cavity was higher than that of ESBL(-) bacteria(P < 0.02); the outcome of properly treated group(sensitive antibiotics were used within 72 hours) was much better than improperly treated group. All ESBL(+) bacteria were sensitive to imipenam, the resistance rate of ESBL(+) bacteria to cefmetazole, amikacin and piperacillin/tazobactam was low; the in vitro activity of ceftazidim to ESBL(+) bacteria was high but the in vivo activity is still under study.
  
  
  CONCLUSIONS
  The mortality of ESBL(+) bacteria infection was high; the outcome would be improved if sensitive antibiotics were chosen as soon as the diagnosis was made.
authors.affiliation: Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
authors.forename: B
authors.initials: B
authors.lastname: Cao
authors.forename: H
authors.initials: H
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Chen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy / Q000401:mortality*; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D001618:beta-Lactamases